戻る
Shanghai Bao Pharmaceuticals Co., Ltd. (02659.HK)価格
02659.HK 株価推移チャート
BAO PHARMA-B (02659.HK)
Shanghai Bao Pharmaceuticals Co., Ltd.
HK$101.6
6.89%
$6.54
レギュラーマーケット： Jan 19, 09:47:03 HKT
データなしFollow-Up Questions
Shanghai Bao Pharmaceuticals Co., Ltd.の主要な財務諸表は何ですか？
02659.HKの主要な財務比率は何ですか？
Shanghai Bao Pharmaceuticals Co., Ltd.の収益はセグメントまたは地域別にどのように分けられていますか？
Shanghai Bao Pharmaceuticals Co., Ltd.は収益を上げていますか？
Shanghai Bao Pharmaceuticals Co., Ltd.に負債はありますか？
Shanghai Bao Pharmaceuticals Co., Ltd.の発行済株式数は何株ですか？
主要データ
前終値
$95
始値
$95.05
当日レンジ
$91.7 - $103.5
52週レンジ
$56 - $101.6
取引高
258.4K
平均取引高
1.0M
1株当たり利益(TTM)
-1.30
配当利回り
--
時価総額
$15.6B
BAO PHARMA-Bとは何ですか？
Shanghai Bao Pharmaceuticals Co Ltd is a CN-based company operating in industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2025-12-10. Shanghai Bao Pharmaceuticals Co Ltd is a China-based company principally engaged in research and development of pharmaceutical products. The firm leverages synthetic biology technology to develop and deliver recombinant biologic drugs, targeting conditions with limited treatment options and complex manufacturing challenges. The firm focuses on four areas, including large-volume subcutaneous drug delivery, antibody-mediated autoimmune conditions, drugs in assisted reproduction and recombinant biologic products as transformative alternative to traditional biochemical production. The Company’s Core Products comprise SJ02 (Slonva), a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP), KJ017, a recombinant human hyaluronidase, and KJ103, an innovative recombinant immunoglobulin G (IgG)-degrading enzyme.